For Managing PCI-Treated ACS, the Highest Proportion of Surveyed MCOs Select Aspirin/Clopidogrel/Enoxaparin and Aspi

However, Only Six Percent of Surveyed Cardiologists Identified the Aspirin/Clopidogrel/Unfractionated Heparin Regimen as Being the Most Efficacious, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the management of percutaneous coronary intervention (PCI)-treated acute coronary syndrome, the highest proportion of surveyed managed care organizations' (MCO) pharmacy directors select aspirin/clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis’s Plavix/Iscover, generics)/enoxaparin (Sanofi-Aventis’s Lovenox/Clexane, generics) and aspirin/clopidogrel/unfractionated heparin as having the best overall clinical profile when compared to other currently-available therapies.

The findings from Decision Resources’ analysis of the PCI-treated acute coronary syndrome market reveal that 35 percent of payers but only six percent of surveyed cardiologists identified the aspirin/clopidogrel/unfractionated heparin regimen as the most efficacious. This result most likely reflects payers’ familiarity with this regimen and the cost-effectiveness associated with generic unfractionated heparin compared with other anticoagulants. In contrast, the fewest surveyed cardiologists chose this regimen as the most efficacious, likely because they recognize its limitations in terms of the incidence of stroke, revascularization and stent thrombosis.

Both surveyed cardiologists and payers perceive the highest unmet need within efficacy in PCI-treated acute coronary syndrome is for therapies that are effective in reducing mortality. The emerging antiplatelet agent ticagrelor (AstraZeneca’s Brilinta/Brilique) has the potential to reduce the incidence of mortality.

“Results of the Phase III PLATO study demonstrated a 22 percent relative risk reduction in all-cause mortality with ticagrelor compared with clopidogrel, equivalent to an absolute risk reduction of 1.4 percent at 12 months,” said Decision Resources Analyst Conor Walsh, Ph.D. “If this reduction in mortality is realized in real world practice, ticagrelor would at least partly satisfy a key unmet need for effective acute coronary syndrome therapies.”

The findings also reveal that, with sales of almost $923 million, the therapy market for acute coronary syndrome in the hospital setting is modest in size and is expected to contract over the next decade as generic versions of key high-priced brands launch. However, the decline in sales decline will be lessened from 2014 to 2019, owing to the launches and uptake of novel antithrombotic therapies. Additionally—due mainly to the genericization of clopidogrel—the post-hospital, prevalent cases acute coronary market will initially contract from $1.3 billion in 2009 to $1.2 billion in 2013 and will then climb to approximately $1.9 billion in 2019, owing to uptake of novel antithrombotics such as Brilinta/Brilique.

Decision Resources’ Robust Market Forecast and Opportunities Analysis

Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2011 advisory service and the DecisionBase 2011 report series.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Cardiology  Pharmaceutical  Professional Services  Consulting  General Health  Managed Care